Cipla gets final nod from US health regulator for lipid regulating Fenofibrate tablets
Indian Drug Major Cipla Has Received Final Nod From The US Health Regulator For Lipid Regulating Fenofibrate Tablets.
Indian drug major Cipla has received final nod from the US health regulator for lipid regulating Fenofibrate tablets.
The company "has received final approval for its abbreviated new drug application (ANDA) for Fenofibrate tablets USP 48mg and 145mg, from the United States Food and Drug Administration (USFDA)," Cipla said in a BSE filing.
The tablets are generic versions of AbbVie's Tricor tablets, it added. "Tricor tablets and generic equivalents had US sales of approximately USD 307 million for the 12-month period ending October 2016, according to IMS Health," Cipla said.
The company's portfolio includes over 1,000 products across a wide range of therapeutic categories. Shares of Cipla were trading 0.76 per cent up at Rs 570.30 on BSE.
For all the Latest Business News, Companies & Commodities News, Download News Nation Android and iOS Mobile Apps.
More from Business
Take Control Of Your Financial Goals: Apply For A Personal Loan Now
Nihal Dangoria: An Indian Entrepreneur Making a Bright Future For The Real Estate Industry
Data breach incident at Extramarks highlights growing cybersecurity concerns in Indian companies
How is ePayLater empowering retailers across the country
Follow your heart, but don't ignore your mind When it comes to investing